Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation

Expert Opinion on Drug Safety, Journal Year: 2023, Volume and Issue: 22(5), P. 355 - 362

Published: May 4, 2023

Biological treatments deeply changed the management of moderate-to-severe forms psoriasis. Among available biological therapies, interleukin (IL)-17 inhibitors, secukinumab, ixekizumab, brodalumab, and bimekizumab represent one most rapid effective biologic classes for Bimekizumab, latest IL-17 inhibitor, is a humanized monoclonal immunoglobulin (Ig)G1 antibody that acts by neutralizing both IL-17A IL-17F, showing unique mechanism action differing from ixekizumab secukinumab (selective IL17A inhibitor), as well brodalumab (antagonist IL17 receptor).This review aims to evaluate safety profile in treatment plaque psoriasis.The efficacy have been reported several phase II III clinical trials, even longer-term period. Moreover, trials also showed significantly higher compared other classes, including anti-TNF, anti-IL-12/23, another secukinumab. Although numerous biologics are currently psoriasis, some patients may result resistant and/or experience psoriatic flares during or after withdrawal. In this scenario, an additional valuable alternative with

Language: Английский

---

The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review

Clinical Cosmetic and Investigational Dermatology, Journal Year: 2022, Volume and Issue: Volume 15, P. 2785 - 2793

Published: Dec. 1, 2022

Teledermatology represented one of the most important and useful tools during COVID-19 pandemic era. Indeed, due to severe restriction, reduce spread infection, different measures were applied among countries hospitals ensure a continuity care for patients. In this scenario, teledermatology played central role, especially in management patients suffering from chronic inflammatory skin diseases. The aim narrative review is describe role analyze main strengths limitations tool, as well provide future perspectives clinical applications.

Language: Английский

---

COVID‐19 vaccination and inflammatory skin diseases

Journal of Cosmetic Dermatology, Journal Year: 2022, Volume and Issue: 22(1), P. 32 - 33

Published: Sept. 26, 2022

The introduction of vaccination campaign is the most important strategy to fight against COVID-19 pandemic.1 In particular, 2 viral vector-based vaccines [Vaxzervria® (AstraZeneca; AZD1222) and vaccine Janssen® (Johnson & Johnson; Ad26.COV2. S)] mRNA [Comirnaty® (Pfizer/BioNTech; BNT162b2) Spikevax® (Moderna; mRNA-1273)] have been authorized in Italy.2 However, different cutaneous adverse reactions reported following vaccination.3 Recently Alelq et al.1 effect on immune-mediated skin diseases (IMSD) based 10 patients seen their outpatient clinics.1 Specifically, among these patients, they found a worsening guttate psoriasis 3 cases bullous pemphigoid (1 case de novo 1 flare pemphigoid), dyshidrotic hand eczema worsening, pustular psoriasis, finally, chilblain-like/gloves socks-like lesion.1 Herein, we also want report experience Southern-Italy Dermatology Centre order highlight relationship between inflammatory diseases. To date, several recorded literature.2 frequent ones are local or delayed at injection site, urticarial, maculopapular, morbilliform papulovesicular eruptions chilblains, livedo vasculitis, swelling cosmetic filling varicella-zoster herpes simplex eruptions, pityriasis rosea-like reactions.3, 4 line with authors, collected our cases' history evaluate how could affect course some chronic diseases, focusing attention hidradenitis suppurativa, pemphigus vulgaris, atopic dermatitis.5, 6 Our cohort study included 14 reporting vaccination, new onset lichen planus, 11 dermatitis, 5 suppurativa,4 finally 7 vulgaris.5 Even if were reported, observed regard patient's dermatologic conditions. suggests that episodes limited self-resolving, non-requiring treatment discontinuation, changing. Moreover, cycle was completed all patients.6 Interestingly, occurred within days after especially second dose.7 No relevant data associated type vaccine, sex, age patients. conclusion agree authors may exacerbate newly induce manifestations; this be explained by activation vaccination-induced innate immunity susceptible individuals. direct two events still under investigation, but factors such as temporal association number reports literature explain causal link. We believe it critical, suggested avoid treatments interfere efficacy so better not carry out therapies methotrexate systemic corticosteroids unless necessary. prevalence IMSD underestimate since who experienced less severe tend self-medicate do seek medical attention. Although physicians should aware possible exacerbations, discouraged from undergoing which always remains safe effective. Martora Fabrizio involved curation, formal analysis, visualization, writing-original draft preparation, review, editing. Villani Alessia conceptualization, validation, original Battista Teresa Fabbrocini Gabriella review editing, supervision. Potestio Luca All read approved final version manuscript. manuscript given written informed consent publication details. Open Access Funding provided Universita degli Studi di Napoli Federico II CRUI-CARE Agreement. Authors no conflict interest. Data current request corresponding author. confirm ethical policies journal, noted journal's author guidelines page, adhered to. approval required article research data.

Language: Английский

---

Reply to ‘Cutaneous adverse effects of the available COVID‐19 vaccines in India: A questionnaire‐based study’ by Bawane J et al.

Journal of the European Academy of Dermatology and Venereology, Journal Year: 2022, Volume and Issue: 36(11)

Published: June 20, 2022

Language: Английский

---

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study

Clinical Cosmetic and Investigational Dermatology, Journal Year: 2023, Volume and Issue: Volume 16, P. 529 - 536

Published: Feb. 1, 2023

Background: Tildrakizumab, an anti-IL-23, showed promising efficacy and safety profiles in two randomized clinical-trials (reSURFACE-1 reSURFACE-2), comparing tildrakizumab superiority to placebo etanercept. Due its recent availability clinical-practice, real-life data are still limited. Objective: To assess the of a real-world-practice patients suffering from moderate-to-severe psoriasis. Methods: A 52-week observational retrospective study enrolled plaque-psoriasis, starting treatment. Results: total 42 were included study. Mean PASI significant reduction at each follow-up (p< 0.001), reducing 13.5± 5.9 baseline, 2.8± 3.8 week-28, resulting stable up week-52. High rates reached both PASI90 PASI100 responses week 16 (PASI90: 52.4%, PASI100: 33.3%) 28 76.1%, 61.9%), maintaining these 52 73.8%, 59.5%). The impact treatment on patient's quality life has been evaluated with DLQI, which during follow-ups. Conclusion: Our confirm as effective generally safe for management psoriasis, high responses, very few reported adverse events, weeks follow-up. Keywords: guselkumab, risankizumab, tildrakizumab, real-world practice, biologics

Language: Английский

---

Lichen planus after COVID-19 infection and vaccination

Archives of Dermatological Research, Journal Year: 2022, Volume and Issue: 315(2), P. 139 - 146

Published: Dec. 5, 2022

Language: Английский

---

JAK Inhibitors in Psoriatic Disease

Clinical Cosmetic and Investigational Dermatology, Journal Year: 2023, Volume and Issue: Volume 16, P. 3129 - 3145

Published: Oct. 1, 2023

Abstract: Psoriasis is now considered to be the cutaneous phenotype of a systemic inflammatory condition, recognized under term Psoriatic Disease (PsD). PsD has several extracutaneous manifestations, such as articular and entheseal involvement, leading psoriatic arthritis (PsA), less frequent intestinal ocular manifestations with colitis/inflammatory bowel disease uveitis, respectively. There have also been reports an increased frequency comorbidities hypertension, diabetes, dyslipidemia, obesity, metabolic syndrome cardiovascular during course PsD. The link between psoriasis related long-term sequela, often characterized by unhealthy lifestyle consequence inflammation; hence, requires adequate prompt treatment, aim controlling not only but inflammation. Pharmacological strategies for significantly over recent years. Recently, targeted synthetic DMARDs, Janus kinase (JAK) inhibitors, tofacitinib upadacitinib, were added therapeutic armamentarium treating PsA, deucravacitinib psoriasis. These oral agents act directly on mechanisms underlining disease, antagonists intracellular JAK signal pathway and, STAT phosphorylation, inhibit gene proinflammatory cytokine transcription. inhibitors represent additional treatment strategy management among these, upadacitinib recently approved In this review we describe ongoing phase II III randomized controlled trials (RCTs) evaluating efficacy safety investigational in PsA. Keywords: plaque psoriasis, arthritis, TYK2

Language: Английский

---

Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data

Immunologic Research, Journal Year: 2023, Volume and Issue: 71(3), P. 328 - 355

Published: Jan. 4, 2023

Language: Английский

---

Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review

Clinical Cosmetic and Investigational Dermatology, Journal Year: 2024, Volume and Issue: Volume 17, P. 51 - 57

Published: Jan. 1, 2024

Abstract: COVID-19 pandemic completely changed every aspect of human life. Several measures were adopted to limit the spreading infection. Among these, vaccination was main one. Globally, campaign a success, showing be efficient in controlling and preventing SARS-Cov2 infection, reducing risk disease progression, hospitalization, mortality. However, with increasing number vaccines administered, several cutaneous reactions described, making dermatologists key players their recognition treatment. also viral reactivations have been described. In particular, cases Pityriasis Rosea (PR) PR-like collected. An early diagnosis is mandatory avoid mistreatments. this context, we conducted review current literature investigating PR following aim understanding possible pathogenetic mechanisms causal correlation as well investigate eruption, offer clinicians wide perspective on linkage between vaccines. Keywords: COVID-19, vaccination, pityriasis rosea, safety

Language: Английский

---

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Clinical Cosmetic and Investigational Dermatology, Journal Year: 2022, Volume and Issue: Volume 15, P. 2369 - 2382

Published: Nov. 1, 2022

Abstract: The outbreak of coronavirus disease 2019 (COVID-19) represented a new worldwide challenge, strongly impacting on the global economy, overall health and lifestyle. Since then, several strategies have been adopted to contain widespread infection. Among these, vaccination is currently most important measure fight against pandemic. However, concerns such as slower-than-hoped-for rollout, hurried approval with limited data, mechanism action (in particular mRNA-based), uncertain duration protection they afforded were initially raised. Moreover, even if cutaneous reactions rarely reported in clinical trials, mass showed dermatologic not recognized, leaving dermatologists decide how diagnose treat them. In this scenario, should be ready promptly recognize these manifestations. Thus, aim manuscript review current literature following COVID-19 vaccination, particularly inflammatory dermatological diseases, order help clinicians better understand conditions provide an extensive overview all vaccine-related skin Keywords: reactions, vaccinations, side effects

Language: Английский

---